Table 3

Number of volunteers who had at least one adverse event

Pooled placebo (n=12)Anifrolumab
300 mg SC (n=6)300 mg IV (n=6)600 mg SC (n=6)
Any AE, n (%)4 (33)3 (50)2 (33)4 (67)
Any AE (with an outcome of death), n (%)0 (0)0 (0)0 (0)0 (0)
Any serious AE*, n (%)0 (0)0 (0)0 (0)0 (0)
Any AE causing discontinuation
of product, n (%)
0 (0)0 (0)0 (0)0 (0)
  • *Includes events with an outcome of death.

  • AE, adverse event; IV, intravenous; SC, subcutaneous.